Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in developed economies. Neovascular or wet-AMD accounts for more than half of all cases of registered sight and severe sight impairment, and approximately 26 000 new cases of wet-AMD develop every year in the UK. 1, 2 There have been major recent advances in the treatment of wet-AMD with the use of biological agents and in particular with vascular endothelial growth factor (VEGF) inhibitor medicationsF frequently termed 'anti-VEGF agents'F following publication of key trial results. [3] [4] [5] These studies showed that wet-AMD patients treated with frequent (monthly or 6 weekly) intra-vitreal injections of anti-VEGF agents had a greatly reduced risk of visual loss compared with no treatment or other existing treatments.
Interim guidelines on the use of anti-VEGF agents based on these key trials were published in 2006. 6 The Royal College of Ophthalmologists (the College) provided guidance on provision of AMD services in 2007. 7 By August 2008, the National Institute for Health and Clinical Excellence (NICE) advised the NHS that such treatment with the anti-VEGF agent ranibizumab (Lucentis; Novartis (Basle, Switzerland) and Genentech (San Francisco, CA, USA) was cost effective. 8 At the same time, guidance from the College clarified treatment recommendations. 9 Thus commissioners of NHS care that is primary care trusts in England and local health boards in Wales have had a duty to commission such care for AMD patients from late 2008, and NHS hospitals have had a duty to comply with the NICE treatment guidelines. As wet-AMD is a common condition and as treatment requirements are frequent, this innovation has consequently required ophthalmic departments to cope with a significant volume of new activity. In a survey of ophthalmology departments undertaken in 2009, the College found there are considerable issues with the provision of anti-VEGF injection therapy in the NHS. 10 The potential for sub-optimal clinical outcomes is real. Significant vision can be lost in a short time if wet AMD is not treated, 11 and this can have a huge impact on independence and quality of life for patients. 12 Following several influential reports on patient safety, learning from clinical failure or incident is now widely regarded as a core principle underpinning improvement in patient safety. 13 The National Patient Safety Agency (NPSA) (http://www.npsa.nhs.uk) was thus initiated. A patient safety incident (PSI) is considered by the NPSA as an unintended or unexpected incident, which could have or did lead to harm for one or more patients. This is also referred to as an adverse event/incident or clinical error and includes 'near misses'. The NPSA includes a system for logging and gathering patient safety incidents (PSIs) at national level following local reporting. NHS organizations in England and Wales now forward local PSI reports to a national reporting and learning system (NRLS) repository database at the NPSA. Direct reporting to the NRLS is also possible.
14 Following a Department of Health review in July 2010, the NPSA will be abolished and it is proposed that some of its functions will be transferred to a Patient Safety subcommittee of the new NHS Commissioning Board. 15 Following the NICE guidance on wet-AMD treatment in 2008 and in the light of the College's concerns in 2009 about development of and provision of services for patients in the modern anti-VEGF era, we reviewed PSI reports on the NRLS database at the NPSA. We sought to identify reported incidents in anti-VEGF treatments in ophthalmic care. We aspired to identify any themes in these reports and to propose, if possible, measures to improve care.
Patients and methods

NHS providers in England and
Wales report PSIs to the NPSA using local electronic submission processes. The information reported includes; clinical specialty, staff involved, location and time of the incident, degree of patient harm, and free text description of the incident. All submitted PSI reports are made anonymous within the NRLS database. Access to review an NRLS search was granted to one of the authors (SPK). The intention of this project was to identify incidents related to anti-VEGF treatments.
A search of the NRLS database by keyword was undertaken in June 2010. All anti-VEGF-related incidents reported from 2003 to the database up to and including June 2010 were included. First, the free text fields were searched for instances of any of the terms: ranibizumab, Lucentis; bevacizumab (Avastin, Roche (Basle, Switzerland) and Genentech) pegaptanib (Macugen, Pfizer, New York, NY, USA) and 'injection' and/or ophthalmology as area of care. Spelling mistakes or wild cards of these words were also considered.
All incident reports so retrieved from the NRLS database were reviewed. Thematic analysis of such cases as reported was undertaken. Our analysis was based on the narrative details provided in such reports only.
Results
The NRLS database held circa 5.5 million incident reports on the 16 June 2010, of which 26 740 records were reported as related to the specialty of ophthalmology. Of these PSI reports, 166 cases/incidents were found relevant and where an anti-VEGF ophthalmic medication agent was mentioned in the report. The study period was from the initial roll out of the NRLS system throughout 2003 and until 16 June 2010. Analysis of the 166 PSIs was undertaken with a view to identify the themes or sources of potential error. Table 1 provides the principal reasons by theme for the anti-VEGF PSI reports. Multiple causal factors were not reported or specifically identifiable on any incident reports. Broadly speaking, where a theme was discernable, safety issues included: infection and inflammation problems; delay in referral, treatment or follow-up; medication availability and mix-ups; problems matching correct patient and to laterality. In our opinion, several of these matters reported revealed themes, which may have preventable measures. Table 2 provides examples of PSI reports. The text of the PSI report and grade of incident severity provided are as reported. Table 3 provides incidents reported by anti-VEGF medication agent and year. Our suggestions for possible measures for prevention or mitigation are presented in Table 4 . 
Discussion
The NRLS database contained close to 27 000 PSI reports related to ophthalmology care from England and Wales by the middle of June 2010.
The data show instances of the wrong patients and wrong eyes receiving intra-vitreal anti-VEGF injections. Medical and surgical confusions (ie, wrong patient, wrong medication, wrong site or side surgery, wrong procedure, or implant) are an infrequent but long recognized and important and preventable cause of patient morbidity and complaint in general, and relevant to ophthalmic surgeons. 16, 17 Under-reporting of PSIs is widespread and recent studies found that only a minority of NHS incidents are reported. 18 Medical staff have barriers to incident reporting and reporting is often nurse-led. [19] [20] [21] Thus, this review almost certainly underestimates the number of anti-VEGF incidents occurring in NHS care during the study period, although it is likely to be indicative of the types of adverse event and near miss which may occur. A weakness of our retrospective review from a data set is that clinical detail of the cases on the data set is scant, and root causation of misadventures is not provided within reports. PSI causation is not described by reporters in a standard format, or at all. Rather PSI reports are provided in free text by the reporter and frequently contain anecdote-based opinion. Furthermore, the severity of patient harm is self-declared by the PSI reporter. The NPSA's guidance '7 Steps to Patient Safety' provides a framework for incident reporting and it includes a classification of severity grading. 22 We cannot tell if this was adhered to. There were cases where patients suffered injections into the wrong eye, but the degree of harm from the original PSI was labeled as 'no harm'. Another potential weakness of the present review is that adverse drug reactions (ADRs) in the UK are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme (http://www.yellowcard.gov.uk) rather than via patient safety reports. Thus our study does not capture any ADR that may have been reported via that mechanism or indeed directly to medication manufacturers or license holders. Nevertheless, this review demonstrates that it is also possible in part to track or monitor patient safety issues arising from a new treatment/procedure introduced into care from about 2006 onwards. Using similar methods of analysis of the NRLS has been undertaken to explore safety reports of certain anesthetic agents. 23 Broadly speaking, safety issues we found included: infection and inflammation problems; delays in treatments; medication availability and mix-ups; problems matching correct patient/eye, and laterality. Many of these are a reflection of the challenges of clinical care such as avoiding healthcare-associated infections and matching correct medications, and data to correct patients. We found similar problems of confusion in ophthalmic care in a review of intra-ocular lens implant incidents reported via the NRLS. 24 Mix-ups causing harm when medications are injected into the wrong part of the eye are a microcosm of medication errors. The inadvertent intra-vitreal injection of cefuroxime Fperhaps intended for sub-conjunctival injectionF instead of ranibizumab (Lucentis) intended for intravitreal injection was reported and led to retinal toxicity and visual loss. Likewise, inadvertent intra-vitreal injection of lidocaine Fintended for ocular surface anesthesiaF instead of ranibizumab (Lucentis) intended for intra-vitreal injection in another two incidents were reported.
This review cannot propose solutions to all the service delivery issues of the introduction of novel treatments. Much service development work is underway on attempting to improve services for wet-AMD patients by the College, patient support groups, and the National Eye Care Plan. However, certain signals emerge from this review and from which some lessons can be learned. Firstly, the widespread recent introduction of intravitreal injections has created a new potential source of healthcare acquired endophthalmitis and intra-ocular inflammation. The reported incidence of endophthalmitis per injection in various studies ranged from 0.02 to 1.9% [3] [4] [5] [25] [26] [27] [28] [29] Several of the cases of infection/ endophthalmitis in such publications were attributed to protocol violations, chief of which was not using an eye lid speculum at the time of injection. 25 With better attention to aseptic technique later in the early key clinical trials, the incidence of post-injection inflammation and infection decreased. A recent metaanalysis of the US literature from 2005 to 2009 reported 52 cases of endophthalmitis after 105 536 intra-vitreal Eye anti-VEGF injections (0.049%). 30 Injection room facilities have been developed for intra-vitreal injection at ophthalmic facilities in the UK. We understand informally from peer discussions that the cases of infectious intra-ocular inflammation/endophthalmitis in NHS care in 2009, may have been due to breaches in asepsis techniques or infrastructure in injection room facilities in two centres. We understand informally that following changes of practise that such episodes have reduced/stopped at those facilities (Discussion at Medical Retina Group Annual Meeting, Oxford, 2010). Intra-vitreal injections are an invasive procedure and are not risk free, and must be taken seriously by all concerned. We stress that eye-care teams undertaking intra-vitreal injections need to be vigilant concerning aseptic technique. The requirement for frequent injections makes this cumulative risk of intra-ocular infection relevant to individual patients. Results of the British Ophthalmic Surveillance Unit (BOSU) study of endophthalmitis cases over the same time period following anti-VEGF injections are awaited with interest. 31 Second, on a service provision level the frequency of anti-VEGF injections or assessments required, to achieve good clinical outcomes in wet-AMD, requires a commitment to commission a service with adequate clinical manpower/infrastructure. It is necessary in our opinion, based on the key clinical trials to ensure that the frequent intra-vitreal injections or clinic assessments required are provided safely and in a timely fashion (usually monthly), in order to provide continuing protection against visual loss. The present patient safety incident reports, highlight capacity has been problematic at times in hospital eye services in England and Wales. This mirrors the concerns of the College's audit on provision of such services in the UK in 2009. 10 We suggest that commissioners and providers agree appropriate service level agreements to ensure that AMD patients receive the appropriate care and in compliance with the relevant NICE guidance. Support from both hospital management and commissioners is needed to ensure such arrangements. Monitoring of patient clinical outcomes is also of merit to ascertain if satisfactory outcomes are being achieved, in what is a challenging new pressure on ophthalmology departments.
Third, many errors with anti-VEGF treatments reported were not complex technological matters or organizational issues. Many problems occurred due to missing clinical records, prescription mix-ups, and communication breakdowns. Again these are a mirror of organizational patient safety challenges.
Fourth, it is important in our experience to maintain a smooth flow during treatment sessions and to keep distractions or interruptions at the lowest possible level.
The Patient Safety First campaign 32 and many similar initiatives recommend both a team brief before surgery and taking 'time out' and a checklist before starting the surgical procedure. The ever-present risk of wrong patient or wrong eye errors in the high-throughput environment of a wet-AMD injection service requires constant vigilance.
Fifth, PSI reports of lack of medication availability and refrigeration failures reflect the relatively high costs of anti-VEGF medications, and the need to order these agents and store them in a refrigerator at a temperature of 2-8 1C. In our opinion, this high medication cost may have stimulated reporting by staff whenever supply problems or waste of such medications occurred. The use of refrigerators with temperature alarms and logs is of merit in the storage of anti-VEGF medication agents. Reliable supply chains for medication delivery to providers at the correct temperature are critical. We have thus suggested that assistance Fincluding replacement of wasted medicationsF from the pharmaceutical suppliers or manufactures to hospital pharmacies be improved upon and await developments.
In relation to systemic safety matters, few reports located were relevant. One report of stroke, other of subdural haemorrhage, and another of possible myocardial infarction following intra-vitreal treatments occurred. Although these are potential side effects of VEGF inhibitor, their proximity to treatment does not necessarily indicate causality. No deaths were reported. Patient safety incident reporting is not an appropriate tool to undertake pharmacovigilance surveillance. Pharmacovigilance is defined by the World Health Organisation as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem'. 33 This is topical in patient care as bevacizumab is not approved for intra-vitreal injection, but is often so used. 34 The present review does not add any additional specific pharmacovigilance signals to those already known in relation to the safety profile of any of the intra-vitreal anti-VEGF medication treatments, approved or un-licensed. Systemic safety signals may perhaps be detectable from healthcare resource usage databases and as signaled in the recent review of Medicare claims following treatment of AMD. 35 In the UK suspected adverse drug reactions (ADR), both systemic and ocular, should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA). ADRs should be reported for both licensed and unlicensed indications, to allow effective monitoring of the safety of medicines in real-life practice. It would be of interest to triangulate our findings with ADR reports on the MHRA's databases. Spontaneous ADR reporting is also thought be an underestimate of ADR events. 36 It should also be recognized that medication safety is more than the monitoring, detection, and assessment of ADRs and that spreading good practise, service improvement, and learning from safety reports is important to improving clinical outcomes. Moving forwards, as anti-VEGF agents also improve clinical outcomes in other retinal patients, such as those affected by diabetic macular edema (DMO) 37 or retinal venous occlusions (RVO), 38 these further treatment developments and emerging guidelines 39 are likely to put further pressures on retinal services and intra-vitreal injection services. Lessons from anti-VEGF use during the roll out phase of such medications in AMD care in England and Wales may assist the extra challenges for DMO and RVO patient management now on the horizon.
In conclusion, this retrospective review of PSIs as reported to a national database demonstrates that learning from such a database has some merit in supporting provision of anti-VEGF medication care in ophthalmology. We encourage ophthalmic teams to undertake more patient safety reporting, both PSI reporting and ADR reporting, in the present anti-VEGF era. The Royal College of Ophthalmologists has provided guidance on patient safety for ophthalmic teams. 40 
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